SLGL News and Press, Sol-Gel Technologies Ltd. From 01/27/23

NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY ® and TWYNEO ® , two innovative dermatology products that were launched ...

Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA Phase 3 study expected to initiate in the second half of 2023, with results expected b...

Sol-Gel Technologies press release ( NASDAQ: SLGL ): Q3 GAAP EPS of -$0.15 misses by $0.08 . Revenue of $0.3M (-96.6% Y/Y) misses by $3.15M . As of September 30, 2022, Sol-Gel had $25.5 million in cash, cash equivalents and deposits, and $9.8 million in marketa...

Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribers Sol-Gel’s cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (N...

NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today th...

Sol-Gel Technologies press release ( NASDAQ: SLGL ): Q2 GAAP EPS of $0.01 beats by $0.11 . Revenue of $3.5M (+288.9% Y/Y) misses by $1.11M . For further details see: Sol-Gel Technologies GAAP EPS of $0.01 beats by $0.11, revenue of $3.5M misses by $1.11M ...

P rescription volumes to date indicate strong uptake, similar to successful dermatology launches Sol-Gel r eceives $3.5 million milestone payment from commercial partner Galderma Holding SA (“Galderma”) for FDA approval o...

NESS ZIONA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced th...

NESS ZIONA, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced tha...

Sol-Gel Technologies press release (NASDAQ:SLGL): Q1 GAAP EPS of -$0.18 beats by $0.11. As of March 31, 2022, Sol-Gel had $30.2 million in cash, cash equivalents and deposits, and $6.1 million in marketable securities for a total balance of $36.3 million. For further details see: Sol-Ge...